Rodolfo Munera, MD
Infectious Disease · Clifton, NJNPI 1154382760
Payments from drug & device makers
Across 317 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$721
- GSK$239
- BD$208
- Amgen$191
- AstraZeneca$184
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$2084%
- Food & beverage$4,79894%
- Education$1092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 115 | $1,757 |
| Viiv Healthcare Company | 52 | $721 |
| GSK | 15 | $239 |
| BD | 2 | $208 |
| Amgen(2 entities) | 13 | $191 |
| AstraZeneca | 12 | $184 |
| Lilly USA, LLC | 11 | $170 |
| Johnson & Johnson | 12 | $155 |
| EMD Serono, Inc. | 10 | $142 |
| Insmed, Inc. | 9 | $142 |
| Amarin Pharma, Inc. | 9 | $124 |
| Exact Sciences | 4 | $107 |
| Dexcom, Inc. | 5 | $102 |
| Medtronic | 2 | $89 |
| Janssen Products, LP | 1 | $85 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $85 |
| Boston Scientific | 5 | $80 |
| Napo Pharmaceuticals Inc | 5 | $68 |
| Novo Nordisk | 4 | $61 |
| Theratechnologies Inc. | 3 | $45 |
| Pfizer | 2 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Merck | 2 | $30 |
| Nevro Corp. | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Paratek Pharmaceuticals, Inc. | 2 | $26 |
| Nabriva Therapeutics, PLC | 2 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Althera Pharmaceuticals LLC | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Shionogi Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FACS$155
- Biktarvy$115
How this compares
$5,115 in reported general payments places this provider in the 80th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 88 | $372,986 |
| JardianceEmpagliflozin | 173 | $166,579 |
| OzempicSemaglutide | 155 | $158,637 |
| EliquisApixaban | 138 | $126,938 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 16 | $97,524 |
| FarxigaDapagliflozin Propanediol | 68 | $89,888 |
| JanumetSitagliptin Phos/Metformin Hcl | 75 | $60,757 |
| DovatoDolutegravir Sodium/Lamivudine | 20 | $60,038 |
| JanuviaSitagliptin Phosphate | 56 | $59,651 |
| XareltoRivaroxaban | 49 | $44,004 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $43,803 |
| RybelsusSemaglutide | 26 | $38,564 |
| TrulicityDulaglutide | 28 | $38,233 |
| LinzessLinaclotide | 44 | $38,233 |
| ProliaDenosumab | 21 | $35,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $1,757 | $372,98688 claims |
| Novo NordiskOzempic, Rybelsus | $61 | $197,201181 claims |
| PfizerEliquis, Abrysvo | $33 | $143,209189 claims |
| MerckJanumet, Januvia, Janumet Xr | $30 | $135,862149 claims |
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay | $721 | $132,36445 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $184 | $101,63983 claims |
| Janssen Products, LPSymtuza | $85 | $97,52416 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $170 | $72,46261 claims |
| AbbVieLinzess, Restasis | $11 | $49,73261 claims |
| Johnson & JohnsonXarelto | $155 | $44,00449 claims |
| AmgenProlia | $191 | $35,64021 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $239 | $30,31996 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Clifton
- Joe NajjarClifton$15K
- Sessine NajjarClifton$13K
- Jihad SlimNewark$6.7M
- Ronald NahassHillsborough$6.1M
- Bindu BalaniHackensack$4.9M
- Suraj SaggarEnglewood$2.9M
- Christopher LucastiSomers Point$2.8M
- Edward LiuNeptune$2.6M
- Keith GottesdienerRahway$2.1M
- Amna YaqubFlemington$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.